DSIP (Delta Sleep-Inducing Peptide)
Awaiting ReclassificationDeep sleep, naturally restored
A 9-residue neuropeptide that promotes deep sleep and modulates the stress response.
Educational content. This page describes DSIP (Delta Sleep-Inducing Peptide) for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed provider before starting, stopping, or modifying any therapy.
- Primary Use
- A 9-residue neuropeptide that promotes deep sleep and modulates the stress response.
- Administration
- injection, nasal
- Typical Cycle
- 10–30 days
- Legal Status
- Awaiting Reclassification
Key Benefits
Pain Modulation
Produces dose-dependent analgesic effects through central mechanisms, offering potential for pain management without opioid-class side effects.[8]
Mitochondrial Protection
Preserves brain mitochondrial respiratory function during hypoxic stress, providing cellular-level neuroprotection during metabolic challenge.[6]
What is DSIP (Delta Sleep-Inducing Peptide)?
Delta sleep-inducing peptide (DSIP, sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a naturally occurring nonapeptide first isolated from rabbit cerebral venous blood in 1977. It was initially identified by its ability to induce delta (slow-wave) sleep in recipient rabbits when transferred via dialyzed blood.
Despite its name suggesting a simple sleep-promoting function, DSIP does much more than just regulate sleep. Research over four decades has revealed stress-protective, analgesic, antioxidant, and neuroendocrine regulatory properties. Paradoxically, the DSIP gene and its specific receptor have never been definitively identified, making it one of the more enigmatic peptides in neuroscience.
How Does It Work?
DSIP's mechanism of action remains incompletely understood. It does not appear to work through a single dedicated receptor. Instead, it acts as a broad neuromodulator that influences multiple neurotransmitter and neuropeptide systems simultaneously.
For sleep promotion, DSIP appears to modulate GABAergic and glutamatergic systems while influencing the circadian pacemaker. It promotes slow-wave sleep architecture (the deep, restorative phase of sleep) rather than simply inducing sedation.
DSIP's stress-protective effects involve modulation of the hypothalamic-pituitary-adrenal (HPA) axis, influencing levels of corticosterone, beta-endorphin, and substance P. Its mitochondrial protective effects during hypoxia suggest an additional direct cellular mechanism.
Quick Facts
Deep sleep, naturally restored
- Primary Use
- A 9-residue neuropeptide that promotes deep sleep and modulates the stress response.
- Administration
- injection, nasal
- Typical Cycle
- 10–30 days
- Categories
- sleep
- Legal Status
- Awaiting reclassification
Mechanism of Action
DSIP functions as a pleiotropic neuromodulator that promotes slow-wave sleep architecture through GABAergic and circadian system modulation, provides stress protection via HPA axis regulation, exerts central analgesia, and preserves mitochondrial respiratory function, acting through multiple parallel mechanisms rather than a single receptor pathway.
Clinical Evidence
Key studies supporting the therapeutic use of this peptide.
DSIP in Chronic Insomnia (Human)
IV DSIP produced longer sleep duration, fewer interruptions, higher sleep quality, more REM sleep, and no daytime sedation.
Schneider-Helmert D, Schoenenberger GA — Experientia, 37(9):913-7 (1981) · PubMed
Sleep Architecture in Cats
Significant decrease in sleep latency and significant increase in total sleep and slow-wave sleep time, confirming effects across species.
Susic V, Masirevic G, Totic S — Brain Res, 414(2):262-70 (1987) · PubMed
Stress Resilience and Neuropeptide Modulation
DSIP modulated substance P, beta-endorphin, and corticosterone levels, enhancing resistance to emotional stress.
Sudakov KV, Coghlan JP, Kotov AV, et al. — Ann N Y Acad Sci, 771:240-51 (1995) · PubMed
Dosing & Administration
Typical protocols used in clinical practice. Always consult a licensed provider for personalized dosing.
Subcutaneous Injection
- Dosage
- 100–300 mcg
- Frequency
- Once daily (evening)
- Cycle
- 10–30 days
Intranasal
- Dosage
- 100–300 mcg
- Frequency
- Once daily (evening)
- Cycle
- 10–30 days
Subcutaneous Injection: Administer 30–60 minutes before intended sleep time.
Intranasal: Alternative to injection with similar timing.
DSIP is typically administered 30–60 minutes before intended sleep time. Effects on sleep architecture develop over the course of the night.
Cycling is commonly recommended (2–4 weeks on, 2–4 weeks off) though the optimal protocol has not been established in large clinical trials.
DSIP is a fragile peptide with a relatively short half-life. Proper storage (frozen, reconstituted fresh) is important for potency.
Side Effects & Safety
Common
- Injection site irritation — Mild redness or discomfort at subcutaneous injection site
Uncommon
- Morning grogginess — Occasional residual drowsiness; less common than with pharmaceutical sleep aids
- Vivid dreams — Increased dream vividness, likely related to enhanced REM sleep
- Headache — Mild transient headache reported by some users
Safety Profile
DSIP has been studied since the late 1970s with a generally favorable safety profile. The clinical insomnia study noted improved sleep without daytime sedation, a significant advantage over most pharmaceutical sleep aids.
The overall clinical evidence base remains limited. The fact that DSIP's specific receptor and gene have not been identified adds uncertainty about its long-term effects.
DSIP's effects on multiple neuropeptide systems mean interactions with other neuroactive substances are theoretically possible. Individuals taking prescription sleep medications or opioids should exercise caution.
Contraindications
- Pregnancy and breastfeeding (insufficient safety data)
- Concurrent use of prescription sleep medications without medical supervision
- Concurrent opioid use (DSIP modulates endorphin systems)
- Severe hepatic or renal impairment (metabolism not fully characterized)
- Active depression (sleep architecture changes may affect mood regulation)
Regulatory Status
Current FDA classification and compounding eligibility.
Under Review (Category 2)
503A CompoundingThe FDA placed this substance in Category 2 of the 503A bulk drug substances evaluation, flagging significant safety risks. 503A compounding carries FDA enforcement risk, so most pharmacies decline to prepare it and many physicians hesitate to prescribe it.
Reclassification Pending
In April 2026, HHS Secretary Robert F. Kennedy Jr. announced that nominators withdrew 12 peptides from Category 2 of the FDA's 503A bulk drug substances evaluation, including this one. The FDA referred them to its Pharmacy Compounding Advisory Committee (PCAC) for re-evaluation at meetings beginning July 2026. If PCAC recommends Category 1 status and the FDA agrees, licensed 503A pharmacies could compound it under FDA enforcement discretion again. The outcome is not final.
Regulatory Detail
Listed in Category 2 under the name Emideltide (DSIP). No human safety data for the proposed routes of administration. FDA cited immunogenicity concerns and lack of clinical justification. Not eligible for compounding.
FDA Action History
Listed as 'Emideltide (DSIP)' in 503A Category 2
What do these terms mean?
- 503A compounding
- Licensed pharmacies that prepare custom prescriptions for individual patients based on a physician's order. 503A is the section of the federal law that governs them.
- 503B outsourcing
- FDA-registered facilities that compound in larger batches under stricter federal oversight (closer to a manufacturer than a pharmacy). Used mostly by hospitals and clinics.
- Bulk drug substance
- The active pharmaceutical ingredient a compounder starts with, before it's made into a finished medication.
- Category 1
- Interim bucket for bulk substances that have been nominated and don't appear to present significant safety risks. 503A pharmacies may compound them under FDA enforcement discretion while the agency continues its review. Not the same as FDA approval.
- Category 2
- Bulk substances the FDA has flagged for significant safety risks. 503A compounding carries FDA enforcement risk, so most pharmacies decline to prepare them and many physicians hesitate to prescribe them.
- PCAC
- Pharmacy Compounding Advisory Committee. The FDA advisory committee that reviews nominated bulk substances and recommends whether they belong in Category 1, Category 2, or on the final 503A Bulks List.
Last verified April 12, 2026. PepHookup tracks public FDA actions. This is not legal or medical advice.
Frequently Asked Questions
Research & References
Ready to explore DSIP (Delta Sleep-Inducing Peptide) therapy?
Looking into DSIP (Delta Sleep-Inducing Peptide)? Find a provider who knows this peptide and can walk you through your options.
Find a Provider